2009
On Mammography — More Agreement Than Disagreement
Partridge AH, Winer EP. On Mammography — More Agreement Than Disagreement. New England Journal Of Medicine 2009, 361: 2499-2501. PMID: 19940286, DOI: 10.1056/nejmp0911288.Peer-Reviewed Original Research
2006
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM, _ _. HER2 testing in breast cancer: NCCN Task Force report and recommendations. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 3: s1-22; quiz s23-4. PMID: 16813731, DOI: 10.6004/jnccn.2006.2003.Peer-Reviewed Original ResearchConceptsBreast cancerHER2 testingHER2 statusIHC scoreMetastatic settingCopies/cellPredictive factorsHER2 expressionTask force membersEvidence-based consensus approachInvasive breast cancerCancer patient evaluationTask ForceBreast cancer panelGene amplificationBreast cancer tumorsAreas of controversyAdjuvant settingHER2 biologyMedical oncologyPatient evaluationClinical trialsMultidisciplinary panelSurgical oncologyHER2NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, _ _. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 1: s1-26. PMID: 16507275, DOI: 10.6004/jnccn.2006.2001.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkBreast cancer treatment guidelinesCancer treatment guidelinesAdjuvant therapyBreast cancerTreatment guidelinesAdjuvant therapy recommendationsQuantitative estrogen receptorComprehensive Cancer NetworkEstrogen receptor levelsPositive breast cancerEndocrine therapyPostmenopausal womenMenopausal statusTask ForcePredictive factorsGuideline panelHER2 statusBiologic markersAromatase inhibitorsTherapy recommendationsReceptor levelsEstrogen receptorHER2/Cancer Network